<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pravastatin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pravastatin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pravastatin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9804" href="/d/html/9804.html" rel="external">see "Pravastatin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11837" href="/d/html/11837.html" rel="external">see "Pravastatin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F55989385"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Statin Pregnancy Contraindication Update</span>
<span class="collapsible-date">July 2021</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">After a comprehensive review of all available data, the FDA is requesting all statin manufacturers to remove the contraindication in the prescribing information against using statins in pregnant patients. Although statin therapy should be discontinued in most pregnant patients, health care providers should consider the ongoing therapeutic needs of the individual patient, especially patients at very high risk of cardiovascular events during pregnancy, such as patients with homozygous familial hypercholesterolemia or those with established cardiovascular disease. Additionally, breastfeeding is still not recommended in patients taking a statin; health care providers should determine whether it is better to temporarily stop statin therapy while breastfeeding or to continue statin therapy and not have the patient breastfeed. If ongoing statin treatment is necessary, infant formula and other alternatives are available. The FDA expects that removing the contraindication will enable health care providers and patients to make individual decisions about benefit and risk, especially for those at very high risk of heart attack or stroke.</p>
<p style="text-indent:0em;">Further information is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy&amp;token=gxfbJKP%2B4jbjRRe1dXCv59qhZFmTmV73qmf%2FX%2BpwMjvINmMExoP9r7EcTZq6LKtsQ%2FwwXarvQCVId0NgjG9XzdICKlsdFJ73s%2FDoyuycmVDaUZCyqN73GrYM2%2BxRAta2zcZQxGheSuTnwZzuZPE4Up8XPwPhb7srLeP9xEjjtcA%3D&amp;TOPIC_ID=12913" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy</a>.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F212522"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Pravachol [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867998"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Pravastatin;</li>
<li>AG-Pravastatin;</li>
<li>APO-Pravastatin;</li>
<li>AURO-Pravastatin;</li>
<li>BIO-Pravastatin;</li>
<li>DOM-Pravastatin [DSC];</li>
<li>JAMP-Pravastatin;</li>
<li>M-Pravastatin;</li>
<li>MAR-Pravastatin;</li>
<li>MINT-Pravastatin;</li>
<li>PMS-Pravastatin;</li>
<li>Pravachol [DSC];</li>
<li>Priva-Pravastatin [DSC];</li>
<li>SANDOZ Pravastatin;</li>
<li>TARO-Pravastatin;</li>
<li>TEVA-Pravastatin</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1061338"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antilipemic Agent</span>;</li>
<li>
<span class="list-set-name">HMG-CoA Reductase Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F212550"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b> Dosage should be individualized according to the baseline low-density lipoprotein cholesterol (LDL-C) level, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8dbf85b0-0aad-4091-93c4-4fe47f31e396">Hyperlipidemia or heterozygous familial and nonfamilial hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperlipidemia or heterozygous familial and nonfamilial hypercholesterolemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Begin treatment if, after adequate trial (6 to 12 months) of intensive lifestyle modification emphasizing body weight normalization and diet, the following are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28437620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28437620'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">LDL-C ≥190 mg/dL or</p>
<p style="text-indent:-2em;margin-left:6em;">LDL-C remains ≥160 mg/dL and two or more cardiovascular risk factors: Family history of premature atherosclerotic cardiovascular disease (&lt;55 years of age), overweight, obesity, or other elements of insulin resistance syndrome or</p>
<p style="text-indent:-2em;margin-left:6em;">LDL-C ≥130 mg/dL and diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18596007','lexi-content-ref-NHLBI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18596007','lexi-content-ref-NHLBI.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Therapy may also be considered for children 8 to 9 years of age meeting the above criteria or for children with diabetes mellitus and LDL-C ≥130 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18596007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18596007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 8 to 13 years: Oral: 20 mg once daily; lower doses (5 and 10 mg/day) have been evaluated and less efficacy observed compared to 20 mg doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NHLBI.1','lexi-content-ref-28685504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NHLBI.1','lexi-content-ref-28685504'])">Ref</a></span>); doses &gt;20 mg have not been studied (Vuorio 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents 14 to 18 years: Oral: 40 mg once daily; lower doses have been evaluated and less efficacy observed; doses &gt;40 mg have not been studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NHLBI.1','lexi-content-ref-28685504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NHLBI.1','lexi-content-ref-28685504'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> Muscle symptoms (potential myopathy): Children ≥8 years and Adolescents: Discontinue use until symptoms can be evaluated; check CPK level; based on experience in adult patients, also evaluate patient for conditions that may increase the risk for muscle symptoms (eg, hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or primary muscle diseases). Upon resolution (symptoms and any associated CPK abnormalities), resume the original or consider a lower dose of pravastatin and retitrate. If muscle symptoms recur, discontinue pravastatin use. After muscle symptom resolution, may then reinitiate a different statin at an initial low dose; gradually increase if tolerated. Based on experience in adult patients, if muscle symptoms or elevated CPK persists for 2 months in the absence of continued statin use, consider other causes of muscle symptoms. If determined to be due to another condition aside from statin use, may resume statin therapy at the original dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NHLBI.1','lexi-content-ref-24222016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NHLBI.1','lexi-content-ref-24222016'])">Ref</a></span>).</p></div>
<div class="block dorp drugH1Div" id="F51204768"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; based on experience in adult patients, dosing adjustment suggested</p></div>
<div class="block dohp drugH1Div" id="F51154926"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer labeling; contraindicated in active liver disease or in patients with unexplained persistent elevations of serum transaminases.</p></div>
<div class="block doa drugH1Div" id="F212527"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9804" href="/d/html/9804.html" rel="external">see "Pravastatin: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Pravastatin 40 to 80 mg/day is considered a moderate-intensity statin (generally reduces low-density lipoprotein cholesterol [LDL-C] by ~30% to 49%). If LDL-C must be lowered ≥50%, select an alternative a high-intensity statin (atorvastatin or rosuvastatin). Assess response ~1 to 3 months after therapy initiation or dose adjustment and every 3 to 12 months thereafter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Use in conjunction with lifestyle modification (eg, diet, exercise). When initiating therapy and selecting dose intensity, consider age, baseline LDL-C, 10-year atherosclerotic cardiovascular disease (ASCVD) risk, risk-enhancing factors, potential adverse effects, and drug interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="355cd99a-0024-4930-8b95-6aee3ac5d71d">Heterozygous familial hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heterozygous familial hypercholesterolemia (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use of pravastatin should be limited to patients unable to tolerate a high-intensity statin. Multiple lipid-lowering therapies may be needed if statin monotherapy is not effective. Referral to a lipid specialist should be considered if treatment goals are not met (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Rosenson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Rosenson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Moderate-intensity therapy: Oral:</b> 40 to 80 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="be04224c-8e9d-4248-8315-86a413718095">Homozygous familial hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Homozygous familial hypercholesterolemia (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use of pravastatin should be limited to patients unable to tolerate a high-intensity statin. Multiple lipid-lowering therapies may be needed if statin monotherapy is not effective. Referral to a lipid specialist should be considered if treatment goals are not met (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Rosenson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Rosenson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Moderate-intensity therapy: Oral:</b> 40 to 80 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b4d76cb4-430b-418c-bf7b-688e7bf30bd0">Prevention of atherosclerotic cardiovascular disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of atherosclerotic cardiovascular disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> If LDL-C goal (eg, percent reduction or absolute goal) is not met with the initial dose, may consider up-titration based on estimated 10-year ASCVD risk (see ACC/AHA ASCVD Risk Estimator Plus online), LDL-C response, and tolerability. If LDL-C goal is not met with maximally tolerated dose, consider switching to a high-intensity statin (atorvastatin or rosuvastatin); additional lipid-lowering therapy may be warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Primary prevention:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients <i>without </i>diabetes, 40 to 75 years of age, and LDL-C 70 to 189 mg/dL:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>ASCVD 10-year risk 5% to &lt;7.5%:</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Depending on baseline LDL-C and presence of risk-enhancing factors, consider statin therapy after shared decision-making with patient. Some experts suggest shared decision-making if ASCVD 10-year risk is 5% to 10%; however, in patients with a baseline LDL-C ≥160 mg/dL, statin therapy is usually recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pignone.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pignone.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Moderate-intensity therapy: Oral:</b> 40 to 80 mg once daily to reduce LDL-C by 30% to 49% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>ASCVD 10-year risk ≥7.5% to &lt;20%:</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Depending on baseline LDL-C and presence of risk-enhancing factors, consider statin therapy after shared decision-making with patient. Some experts suggest initiating moderate-intensity statin therapy in most patients if ASCVD 10-year risk is &gt;10% to &lt;20% and LDL-C is &gt;100 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pignone.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pignone.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Moderate-intensity therapy: Oral:</b> 40 to 80 mg once daily to reduce LDL-C by 30% to 49%; higher-risk patients with multiple risk-enhancing factors may benefit from high-intensity statin therapy (ie, with atorvastatin or rosuvastatin) to reduce LDL-C by ≥50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>ASCVD 10-year risk ≥20% (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Use of pravastatin should be limited to patients unable to tolerate a high-intensity statin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>
<b>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</b></i></p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Moderate-intensity therapy: Oral:</b> 40 to 80 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients <i>with</i> diabetes:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Age 40 to 75 years </i>without <i>additional ASCVD risk factors</i></b>
<i>
<b>:</b></i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Moderate-intensity therapy: Oral:</b> 40 to 80 mg once daily to reduce LDL-C by 30% to 49% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>ASCVD 10-year risk ≥7.5% or multiple ASCVD risk factors (alternative agent)</i>
<i>:</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Use of pravastatin should be limited to patients unable to tolerate a high-intensity statin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-36031461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-36031461'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</i></b></p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Moderate-intensity therapy: Oral:</b> 40 to 80 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients with LDL-C ≥190 mg/dL and 20 to 75 years of age (regardless of ASCVD risk estimate or coexisting diabetes mellitus) (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Use of pravastatin should be limited to patients unable to tolerate a high-intensity statin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>
<b>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</b></i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Moderate-intensity therapy: Oral:</b> 40 to 80 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Secondary prevention in patients with established atherosclerotic cardiovascular disease (eg, coronary heart disease, cerebrovascular disease [ischemic stroke or transient ischemic attack], peripheral arterial disease) (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Use of pravastatin should be limited to patients unable to tolerate a high-intensity statin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Rosenson.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Rosenson.2'])">Ref</a></span>). Patients with high-risk ASCVD may require additional therapies to achieve LDL-C goal (eg, &lt;70 mg/dL or &lt;50 mg/dL if very high risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-Rosenson.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-Rosenson.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Patients unable to tolerate high-intensity therapy (eg, appropriate dose of atorvastatin or rosuvastatin):</b></i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Moderate-intensity therapy: Oral:</b> 40 to 80 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ecca964d-8cd8-4a02-ba31-39237595cbed">Transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Transplantation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Certain immunosuppressive drugs can induce or exacerbate hypercholesterolemia. Significant drug interactions between statins and immunosuppressant drugs are frequent; some interactions can increase statin serum concentrations and risk of toxicity (eg, myopathy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27754879','lexi-content-ref-Eisen.1','lexi-content-ref-20643330','lexi-content-ref-24323134','lexi-content-ref-Lentine.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27754879','lexi-content-ref-Eisen.1','lexi-content-ref-20643330','lexi-content-ref-24323134','lexi-content-ref-Lentine.1'])">Ref</a></span>). Consult drug interactions database for more detailed information.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transplantation, post heart (off-label use): Oral:</b> Initial: 20 mg once daily starting 1 to 2 weeks after transplant, regardless of baseline cholesterol levels; increase to the maximum tolerated dose within 4 to 8 weeks of transplantation based on response and concomitant drugs up to 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27754879','lexi-content-ref-Eisen.1','lexi-content-ref-20643330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27754879','lexi-content-ref-Eisen.1','lexi-content-ref-20643330'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transplantation, post kidney (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> The decision to initiate therapy for primary or secondary prevention is similar to the nontransplant population (see "Use: Prevention of atherosclerotic cardiovascular disease"). However, in patients who are 30 to 39 years of age, some experts suggest statin therapy post-kidney transplantation for primary prevention of ASCVD. For primary prevention of ASCVD in patients 18 to 29 years of age, use shared decision making while considering risks and benefits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lentine.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lentine.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 20 mg once daily; increase dose based on response, tolerability, and concomitant drugs up to 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27754879','lexi-content-ref-Lentine.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27754879','lexi-content-ref-Lentine.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991647"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;30 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1613121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1613121'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤30 mL/minute: Initial: 10 mg once daily. May increase based on efficacy and tolerability up to the indication-specific usual recommended dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15860377','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15860377','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9403282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9403282'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend <b>not </b>initiating a statin in dialysis patients due to lack of benefits shown in this population; however, patients initiated on a statin before progressing to dialysis may continue to receive therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24323134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24323134'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Dose as for CrCl ≤30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9403282','lexi-content-ref-7606882','lexi-content-ref-Expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9403282','lexi-content-ref-7606882','lexi-content-ref-Expert.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> KDIGO guidelines recommend <b>not </b>initiating a statin in dialysis patients due to lack of benefits shown in this population; however, patients initiated on a statin before progressing to dialysis may continue to receive therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24323134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24323134'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b>: Dose as for CrCl ≤30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7606882','lexi-content-ref-Expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7606882','lexi-content-ref-Expert.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Dose as for CrCl ≤30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b>
<b>Oral:</b> Dose as for CrCl ≤30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988949"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, Jeong Park, PharmD, MS, BCTXP, FCCP, FAST, Arun Jesudian, MD, Sasan Sakiani, MD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although use is contraindicated in patients with active liver failure or decompensated cirrhosis according to the manufacturer's labeling, baseline elevation in AST/ALT should not preclude use of statins for compelling indications in patients with chronic stable liver disease including compensated cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774','lexi-content-ref-32139553','lexi-content-ref-15131789','lexi-content-ref-29684459','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774','lexi-content-ref-32139553','lexi-content-ref-15131789','lexi-content-ref-29684459','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Hepatic impairment prior to treatment initiation: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class A: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17668878']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17668878'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class B: Oral</b>: 40 mg once daily; maximum: 40 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Singh.1','lexi-content-ref-33726685','lexi-content-ref-28839820','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Singh.1','lexi-content-ref-33726685','lexi-content-ref-28839820','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class C: </b>Use generally not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Acute hepatotoxicity or worsening of hepatic function (eg, progression from Child-Turcotte-Pugh class A to B) during treatment:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progression from baseline to Child-Turcotte-Pugh class A through C: </b>Although use is contraindicated in patients with active liver failure or decompensated cirrhosis according to the manufacturer's labeling, if pravastatin-induced hepatotoxicity (eg, liver injury, rhabdomyolysis) has been ruled out, may continue current dose for hypercholesterolemia and atherosclerotic cardiovascular disease risk management, not to exceed 80 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29684459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29684459'])">Ref</a></span>); however, in patients with decompensated cirrhosis, consider not exceeding 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Singh.1','lexi-content-ref-33726685','lexi-content-ref-28839820','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Singh.1','lexi-content-ref-33726685','lexi-content-ref-28839820','lexi-content-ref-Expert.DOH'])">Ref</a></span>). Continued use of statin therapy may be hepatoprotective in patients with decompensated cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Singh.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Singh.1'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F55674122"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Statins are associated with <b>increased serum transaminases</b> and hepatotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575','lexi-content-ref-19826975']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575','lexi-content-ref-19826975'])">Ref</a></span>). Asymptomatic transient or persistent increases both &lt;3 or &gt;3 times the ULN in serum transaminases may occur with all statins; the <b>increased serum alanine aminotransferase</b> (ALT) is typically greater than the <b>increased serum aspartate aminotransferase</b> (AST) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>). <b>Acute hepatotoxicity</b> has been documented (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10235223','lexi-content-ref-25075655','lexi-content-ref-24700436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10235223','lexi-content-ref-25075655','lexi-content-ref-24700436'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Upon dose reduction or discontinuation, transaminase levels return to or near pretreatment levels; although, mild elevations resolve with continued use in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16581330','lexi-content-ref-24729773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16581330','lexi-content-ref-24729773'])">Ref</a></span>). Chronic liver injury (defined as liver biochemical or histological abnormalities that persisted for 6 months or more after onset) has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24700436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24700436'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unclear; pravastatin undergoes minimal hepatic metabolism. Changes in the lipid components of the hepatocyte membrane may lead to increased permeability and leakage of liver enzymes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20360293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20360293'])">Ref</a></span>). Pravastatin may induce liver mitochondrial redox imbalance, which may contribute to hepatotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30653440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30653440'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most cases occur within the first 3 months of initiation or dose escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15198967','lexi-content-ref-21889469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15198967','lexi-content-ref-21889469'])">Ref</a></span>). Duration of pravastatin prior to hepatotoxicity has been reported from approximately 7 weeks to 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10235223','lexi-content-ref-24700436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10235223','lexi-content-ref-24700436'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses may increase the risk of liver injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24829162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24829162'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications with statin drug-drug interactions or hepatotoxic properties (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16581330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16581330'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hepatotoxicity is more commonly associated with atorvastatin than pravastatin, rosuvastatin, and simvastatin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21889469','lexi-content-ref-27860156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21889469','lexi-content-ref-27860156'])">Ref</a></span>). Fluvastatin is associated with the greatest risk of developing hepatotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30716508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30716508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between different statins and the susceptibility to hepatotoxicity is unknown, as data have shown conflicting results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27860156','lexi-content-ref-20360293','lexi-content-ref-32313740','lexi-content-ref-19826975']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27860156','lexi-content-ref-20360293','lexi-content-ref-32313740','lexi-content-ref-19826975'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic hepatitis B and alcohol consumption are independent risk factors for hepatic aminotransferase elevation associated with statins in patients 80 years of age or older (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31842780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31842780'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Muscle-related effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Statins are associated with several muscle-related effects, including:</p>
<p style="text-indent:-2em;margin-left:4em;">• <b>Myalgia</b> (muscle symptoms without significant creatine kinase [CK] elevations; also known as statin-associated muscle symptoms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29473763','lexi-content-ref-25694464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29473763','lexi-content-ref-25694464'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">• <b>Myopathy</b> (defined as unexplained muscle pain or weakness accompanied by a CK &gt;10 times the ULN) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">• <b>Rhabdomyolysis</b> (CK &gt;40 times the ULN) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>) often with acute renal failure secondary to myoglobinuria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29496886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29496886'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">• <b>Immune-mediated necrotizing myopathy</b> (IMNM) (elevated CK plus the presence of autoantibodies against HMG-CoA reductase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30430215','lexi-content-ref-28277343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30430215','lexi-content-ref-28277343'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Uncertain; alterations in the mevalonate pathway and changes in the electrical and structural characteristics of the sarcolemma related to calcium ion flux possibly contribute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18001622']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18001622'])">Ref</a></span>). Decreased ubiquinone, which is essential for energy production in skeletal muscle, may also contribute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30032220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30032220'])">Ref</a></span>). Myopathy/rhabdomyolysis risk is related to circulating active drug concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16581332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16581332'])">Ref</a></span>). IMNM is considered an immune-mediated process; autoantibodies against HMG-CoA reductase (anti-HMG-CoA) have been identified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26886523','lexi-content-ref-28277343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26886523','lexi-content-ref-28277343'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; often presents within a few months after starting therapy (highest risk within first year of use), when the dose of the statin is increased, or when introducing an interacting drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575','lexi-content-ref-25694464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575','lexi-content-ref-25694464'])">Ref</a></span>). Muscle symptoms often appear more promptly when patients are reexposed to the same statin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25694464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25694464'])">Ref</a></span>). Duration of statin use prior to development of IMNM is ~2 to 3.5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30430215','lexi-content-ref-28277343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30430215','lexi-content-ref-28277343'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• First year of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dose increase (for myopathy and rhabdomyolysis, but not IMNM) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30430215','lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30430215','lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Addition of an interacting drug (eg, concurrent use of medications associated with myopathy [eg, gemfibrozil]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>). Since there is minimal metabolism of pravastatin by CYP3A4, low risk for clinically significant drug interactions with CYP3A4 inhibitors; however, concomitant use of inhibitors of OATP1B1 (eg, cyclosporine) or OATP1B3 may result in increased pravastatin plasma levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32729746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32729746'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypothyroidism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting muscle disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30580575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30580575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27484241']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27484241'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low body mass index (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20628837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20628837'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Heavy exercise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20628837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20628837'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20628837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20628837'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher HMG-COA reductase inhibitory activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30443347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30443347'])">Ref</a></span>), rosuvastatin &gt; atorvastatin &gt; simvastatin &gt; pravastatin ≈ lovastatin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22936996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22936996'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F212488"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (25%)<span class="lexi-table-link-container"> (<a aria-label="Pravastatin: Adverse Reaction: Musculoskeletal Pain table link" class="lexi-table-link" data-table-id="lexi-content-pravastatin-adverse-reaction-musculoskeletal-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pravastatin-adverse-reaction-musculoskeletal-pain')">table 1</a>)</span><span class="table-link" style="display:none;">Pravastatin: Adverse Reaction: Musculoskeletal Pain</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pravastatin: Adverse Reaction: Musculoskeletal Pain" frame="border" id="lexi-content-pravastatin-adverse-reaction-musculoskeletal-pain" rules="all">
<caption style="text-align:center;">
<b>Pravastatin: Adverse Reaction: Musculoskeletal Pain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pravastatin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pravastatin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10,764</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10,719</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (21%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Respiratory: Cough (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Neuromuscular &amp; skeletal: Myopathy</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Increased serum creatine kinase</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, lichen planus, skin changes (including changes to hair/nails, discoloration, dryness of mucous membranes, nodules), skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (de Graaf 2004), diabetes mellitus (including exacerbation of diabetes mellitus) (Ohmura 2005), elevated glycosylated hemoglobin (Ohmura 2005), gynecomastia, increased in fasting plasma glucose, thyroid dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, constipation, pancreatitis (Tarar 2021; Tsigrelis 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (interstitial) (Huang 2015), dysuria, nocturia, urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, hemolytic anemia, increased erythrocyte sedimentation rate, positive ANA titer, purpuric disease</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatotoxicity (Hartleb 1999), cholestatic jaundice, fulminant hepatic necrosis, hepatic cirrhosis, hepatic failure, hepatic neoplasm, hepatitis, increased serum transaminases, liver steatosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Dermatomyositis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, chills, cranial nerve disorder (including dysgeusia, facial paresis, impairment of extraocular movement), malaise, myasthenia (Purvin 2006), nightmares, peripheral nerve palsy</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, arthritis, immune-mediated necrotizing myopathy (Essers 2019), lupus-like syndrome, myalgia (Selva-O’Callaghan 2018, Stroes 2015), polymyalgia rheumatica, polymyositis, rhabdomyolysis (Takei 1999), tendinopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, interstitial pulmonary disease, pleural effusion (Kalomenidis 2007)</p></div>
<div class="block coi drugH1Div" id="F212503"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to pravastatin or any component of the formulation; active liver disease or decompensated cirrhosis.</p></div>
<div class="block war drugH1Div" id="F212485"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes mellitus: Increases in HbA<sub>1c</sub> and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myopathy/rhabdomyolysis: Discontinue therapy in any patient in which CPK levels are markedly elevated (&gt;10 times ULN) or if myopathy is suspected/diagnosed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients who consume large amounts of ethanol and/or have a history of liver disease. May require dosage adjustment in some patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: May rarely worsen or precipitate myasthenia gravis (MG); monitor for worsening MG if treatment is initiated (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special Populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in patients with advanced age, these patients are predisposed to myopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: Based on current research and clinical guidelines, HMG-CoA reductase inhibitors should be continued in the perioperative period for noncardiac and cardiac surgery (ACC/AHA [Fleisher 2014]; ACC/AHA [Hillis 2011]). Perioperative discontinuation of statin therapy is associated with an increased risk of cardiac morbidity and mortality.</p></div>
<div class="block foc drugH1Div" id="F212496"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pravachol: 20 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pravachol: 40 mg [DSC] [contains fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 40 mg, 80 mg</p></div>
<div class="block geq drugH1Div" id="F212481"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F212505"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Pravastatin Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $2.61 - $3.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $2.83 - $3.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $4.17 - $4.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $4.79</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867999"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pravachol: 20 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pravachol: 40 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 40 mg</p></div>
<div class="block admp drugH1Div" id="F52613647"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be taken without regard to meals or time of day; administer at least 1 hour before or 4 hours after bile acid resins.</p></div>
<div class="block adm drugH1Div" id="F212500"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b>Administer without regard to meals.</p></div>
<div class="block sts drugH1Div" id="F212517"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53568497"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjunct to dietary therapy in patients with heterozygous familial hypercholesterolemia (HFH) hypercholesterolemia if LDL-C remains ≥190 mg/dL or if ≥160 mg/dL with family history of premature cardiovascular (CVD) or presence of ≥2 cardiovascular risk (FDA approved in children ≥8 years of age and adolescents). Adjunct to dietary therapy to decrease elevated serum total and low density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo-B), and triglyceride levels, and to increase high density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia (heterozygous, familial, and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb; FDA approved in adults); adjunct to dietary therapy in patients with isolated hypertriglyceridemia (Fredrickson type IV; FDA approved in adults); treatment of primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet (FDA approved in adults); primary and secondary prevention of cardiovascular disease in high risk patients (FDA approved in adults); primary prevention of cardiovascular disease in high-risk patients (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F212578"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">HMG-CoA reductase inhibitors (when referred to as "statins") may be confused with nystatin.</p>
<p style="text-indent:-2em;margin-left:4em;">Pravachol may be confused with Prevacid, Prinivil, propranolol</p>
<p style="text-indent:-2em;margin-left:4em;">Pravastatin may be confused with atorvastatin, nystatin, pitavastatin, prasugrel</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F212564"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), OAT1/3, OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F212490"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: May increase the serum concentration of Pravastatin. Management: Limit the pravastatin dose to a maximum of 40 mg per day when used with antihepaciviral combination products and monitor patients for evidence of pravastatin toxicities (eg, myopathy).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May increase the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bempedoic Acid: May increase the serum concentration of Pravastatin. Management: Avoid coadministration of bempedoic acid with pravastatin doses greater than 40 mg due to the potential for increased pravastatin concentrations and pravastatin-related myopathy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Avoid use of bezafibrate and HMG-CoA reductase inhibitors (statins) unless strictly indicated due to the increased of muscle toxicity (including rhabdomyolysis). In patients who may be predisposed to myopathy, concomitant use is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Pravastatin. Management: Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered, benefits should be carefully weighed against the risks, and patients should be monitored closely for signs/symptoms of muscle toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: May increase the serum concentration of Pravastatin. Management: Limit pravastatin to a maximum of 40 mg/day when used in combination with clarithromycin. If this combination is used, monitor patients more closely for evidence of pravastatin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Colchicine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May increase the serum concentration of Pravastatin. Pravastatin may increase the serum concentration of CycloSPORINE (Systemic). Management: Initiate pravastatin dose at 10 mg daily and limit the maximum pravastatin dose to 20 mg daily in patients who are also receiving cyclosporine. Monitor for pravastatin toxicities (eg, myalgia, myopathy, rhabdomyolysis) if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DAPTOmycin: HMG-CoA Reductase Inhibitors (Statins) may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping statin (HMG-CoA reductase inhibitor) therapy prior to daptomycin. If daptomycin is used with a statin, creatine phosphokinase (CPK) monitoring could be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: May increase the serum concentration of Pravastatin. This effect has been demonstrated with darunavir/ritonavir and may occur with darunavir/cobicistat. The individual contributions of darunavir, ritonavir, and cobicistat are unknown.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: May decrease the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May increase the serum concentration of Pravastatin. Management: Limit pravastatin dose to a maximum of 40 mg/day when used in combination with erythromycin. If this combination is used, monitor patients more closely for evidence of pravastatin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenofibrate and Derivatives: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostemsavir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest possible starting statin dose and monitor patients closely for statin-related adverse effects (eg, muscle aches and pains) during coadministration with fostemsavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use whenever possible. Use is listed as contraindicated in product characteristic summaries in several countries, although UK labeling suggests that use could be considered under exceptional circumstances and with close supervision.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest statin dose possible if combined with glecaprevir/pibrentasvir and monitor for increased statin effects/toxicities. Avoid concomitant use with atorva-, simva-, or lovastatin. Limit rosuvastatin to 10 mg daily and reduce pravastatin dose 50%<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Administer HMG-CoA reductase inhibitors (eg, statins) at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: May decrease the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PARoxetine: Pravastatin may enhance the adverse/toxic effect of PARoxetine. Specifically, blood glucose elevations may occur with the combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rupatadine: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for increased CPK and/or other muscle toxicities may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: May decrease the serum concentration of Pravastatin. This effect has only been demonstrated with saquinavir/ritonavir. The individual contributions of saquinavir and ritonavir are unknown.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: May increase the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: HMG-CoA Reductase Inhibitors (Statins) may enhance the myopathic (rhabdomyolysis) effect of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors). Management: Avoid concurrent use with OATP1B1/1B3 substrates for which small changes in exposure may be associated with serious toxicities. Monitor for evidence of an altered response to any OATP1B1/1B3 substrate if used together with trofinetide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors (Statins) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest statin dose possible if combined with voxilaprevir and monitor patients for increased statin effects/toxicities. Avoid concomitant use of voxilaprevir with rosuvastatin or pitavastatin, and limit pravastatin doses to 40 mg daily.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F212507"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Before initiation of therapy, patients should be placed on a standard cholesterol-lowering diet for 6 weeks and the diet should be continued during drug therapy.  </p>
<p style="text-indent:0em;margin-top:2em;">Red yeast rice contains variable amounts of several compounds that are structurally similar to HMG-CoA reductase inhibitors, primarily monacolin K (or mevinolin) which is structurally identical to lovastatin; concurrent use of red yeast rice with HMG-CoA reductase inhibitors may increase the incidence of adverse and toxic effects (Lapi 2008; Smith 2003). </p></div>
<div class="block rep_considerations drugH1Div" id="F49321568"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Adequate contraception is recommended if an HMG-CoA reductase inhibitor (statin) is required in patients who may become pregnant (AHA/ACC [Grundy 2019]; CCS [Pearson 2021]). Patients planning to become pregnant should discuss their lifetime risk of cardiovascular disease, as well as risks and benefits of statin therapy with their health care team (CCS [Pearson 2021]). When appropriate, statins can be discontinued 1 to 2 months prior to conception (AHA/ACC [Grundy 2019]).</p>
<p style="text-indent:0em;margin-top:2em;">When a statin is needed in a patient of reproductive potential, a more hydrophilic option (eg, pravastatin, rosuvastatin) may be preferred to limit placental transfer (CCS [Pearson 2021]).</p></div>
<div class="block pri drugH1Div" id="F212506"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Pravastatin crosses the placenta (Ahmed 2020; Costantine 2016; Costantine 2021; Nanovskaya 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Cord blood concentrations were near or below the limit of quantification (&lt;0.1 ng/mL) in 10 women administered pravastatin 10 mg once daily (Costantine 2016). Following administration of pravastatin 10 mg once daily to 1 patient during pregnancy, the estimated placental transfer was 25.5%; pravastatin was not detected in the infant serum 4 days after delivery. In a second patient administered pravastatin 10 mg once daily during pregnancy, the estimated placental transfer was 23.8% of the maternal dose, and pravastatin was not detected in infant serum when measured 1 day after birth (Saito 2021).</p>
<p style="text-indent:0em;margin-top:2em;">In healthy pregnancies, changes in lipid synthesis occur that are required for normal placental and fetal growth. Low-density lipoprotein cholesterol and triglycerides increase as pregnancy progresses and decline postpartum. HMG-CoA reductase inhibitors (statins) decrease the synthesis of cholesterol and substances derived from cholesterol. Therefore, based on the mechanism of action, in utero exposure may cause fetal harm (Lecarpentier 2012); however, data from available studies have not shown an increased risk of major congenital anomalies following first trimester exposure (Bateman 2015; Chang 2021; Vahedian-Azimi 2021a). Additional data are needed to evaluate other pregnancy outcomes, such as miscarriage (Vahedian-Azimi 2021b).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of pravastatin may be altered (limited data) (Costantine 2016; Costantine 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Because there is potential for fetal harm, statins should be discontinued once pregnancy is recognized (AHA/ACC [Grundy 2019]; Brunham 2018). If lipid-lowering therapy during pregnancy is required, it should be individualized based on the therapeutic needs of the patient, considering the lifetime risk of untreated disease, use of nonstatin therapies, as well as the known risks and benefits of statins. Based on limited data, when a statin is needed in a pregnant patient, a more hydrophilic option (eg, pravastatin, rosuvastatin) may be preferred. Lipophilic statins (eg, atorvastatin, fluvastatin, lovastatin, simvastatin, pitavastatin) may be more likely to cross the placenta and increase the risk of congenital malformations (AHA/ACC [Grundy 2019]; CCS [Pearson 2021]; Lecarpentier 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Additional data are needed to clarify the role of statins for the prevention of atherosclerotic cardiovascular disease in at-risk pregnant patients (AHA/ACC [Grundy 2019]; AHA [Parikh 2021]; CCS [Pearson 2021]).</p></div>
<div class="block mopp drugH1Div" id="F53568476"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Manufacturer's labeling: Consider neuromuscular and serologic testing if immune-mediated necrotizing myopathy is suspected.​</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric patients: Baseline: ALT, AST, and creatine phosphokinase levels (CPK); fasting lipid panel (FLP) and repeat ALT and AST should be checked after 4 weeks of therapy; if no myopathy symptoms or laboratory abnormalities, then monitor FLP, ALT, and AST every 3 to 4 months during the first year and then every 6 months thereafter (NHLBI 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Adults:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>2013 ACC/AHA Blood Cholesterol Guideline recommendations (Stone 2013):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Lipid panel (total cholesterol, HDL, LDL, triglycerides):</b> Baseline lipid panel; fasting lipid profile within 4 to 12 weeks after initiation or dose adjustment and every 3 to 12 months (as clinically indicated) thereafter. If 2 consecutive LDL levels are &lt;40 mg/dL, consider decreasing the dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Hepatic transaminase levels:</b> Baseline measurement of hepatic transaminase levels (ie, ALT); measure hepatic function if symptoms suggest hepatotoxicity (eg, unusual fatigue or weakness, loss of appetite, abdominal pain, dark-colored urine or yellowing of skin or sclera) during therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>CPK:</b> CPK should not be routinely measured. Baseline CPK measurement is reasonable for some individuals (eg, family history of statin intolerance or muscle disease, clinical presentation, concomitant drug therapy that may increase risk of myopathy). May measure CPK in any patient with symptoms suggestive of myopathy (pain, tenderness, stiffness, cramping, weakness, or generalized fatigue).</p>
<p style="text-indent:-2em;margin-left:6em;">Evaluate for new-onset diabetes mellitus during therapy; if diabetes develops, continue statin therapy and encourage adherence to a heart-healthy diet, physical activity, a healthy body weight, and tobacco cessation.</p>
<p style="text-indent:-2em;margin-left:6em;">If patient develops a confusional state or memory impairment, may evaluate patient for nonstatin causes (eg, exposure to other drugs), systemic and neuropsychiatric causes, and the possibility of adverse effects associated with statin therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer recommendations:</i> Liver enzyme tests at baseline and repeated when clinically indicated. <b>Upon initiation or titration, lipid panel should be analyzed at intervals of 4 weeks or more. </b></p></div>
<div class="block pha drugH1Div" id="F212484"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pravastatin is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is the rate-limiting enzyme involved in <i>de novo</i> cholesterol synthesis. In addition to the ability of HMG-CoA reductase inhibitors to decrease levels of high-sensitivity C-reactive protein (hsCRP), they also possess pleiotropic properties including improved endothelial function, reduced inflammation at the site of the coronary plaque, inhibition of platelet aggregation, and anticoagulant effects (de Denus 2002; Ray 2005).</p></div>
<div class="block phk drugH1Div" id="F212502"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Several days</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Peak effect: 4 weeks</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LDL-reduction: 40 mg/day: 34% (for each doubling of this dose, LDL-C is lowered by ~6%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapidly absorbed; average absorption 34%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 0.46 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~50%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic multiple metabolites; primary metabolite is 3 alpha-hydroxy-iso-pravastatin (2.5% to 10% activity of parent drug); extensive first-pass metabolism</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 17%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children and Adolescents (4.9 to 15.6 years): 1.6 hours; range: 0.85 to 4.2 hours (Hedman 2003)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults: 77 hours (including all metabolites); Pravastatin: ~2 to 3 hours (Pan 1990); 3 alpha-hydroxy-iso-pravastatin: ~1.5 hours (Gustavson 2005) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 1 to 1.5 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (70%); urine (~20%, 8% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51219951"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Mean AUC was approximately 27% greater and mean cumulative urinary excretion was approximately 19% lower in elderly men. Mean AUC was approximately 46% higher and mean cumulative urinary excretion was approximately 18% lower in elderly women.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F212508"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lipostat</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Pravacol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Panchol | Pravachol | Pravastatin +pharma | Pravastatin 1a pharma gmbh | Pravastatin genericon pharma | Pravastatin hexal pharma | Pravastatin interpharm | Pravastatin ratiopharm | Pravastatin sandoz | Sanaprav | Selipran</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo pravastatin | Auro pravastatin | Chemmart Pravastatin | Cholstat | Cholvastin | Genrx Pravastatin | Liprachol | Pravachol | Pravastatin | Pravastatin actavis | Pravastatin an | Pravastatin Generic Health | Pravastatin ps | Pravastatin RL | Pravastatin sandoz | Pravastatin Winthrop | Pravastatin-GA | Terry White Chemists Pravastatin | Vastoran</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Docpravastatine | Prareduct | Pravasine | Pravastatin ab | Pravastatine Arrow | Pravastatine bexal | Pravastatine eg | Pravastatine ratiopharm | Pravastatine Sandoz | Pravastatine sodium accord | Pravastatine teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Lipostat | Pravastatin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Lenitral | Mevalotin | Pravacol | Pravastat Sodic | Pravastatina sodica</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mevalotin | Prava-Med | Pravalotin | Pravalotin Mepha | Pravasta eco | Pravastatin actavis | Pravastatin Axapharm | Pravastatin mepha | Pravastatin spirig | Pravastatin teva | Pravastatin zentiva | Pravastatin-1 A Pharma | Pravastax | Selipran</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Pravastor</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Pravacol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Fu li ta zhi | Fu ta ning | Mei bai le zhen | Mevalotin | Pravachol | Pu hui zhi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Pranvalotin | Pravacol | Pravalip | Pravalotin | Pravastatina | Pravax | Pravyl</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Lipostat | Vitastat</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lipifacil | Liprevil | Mevalotin | Mevalotin protect | Prava | Prava basic | Prava Q | Pravabeta | Pravagamma | Pravagodur | Pravalich | Pravalip | Pravasin | Pravasin protect | Pravastatin | Pravastatin AAA | Pravastatin Accord | Pravastatin actavis | Pravastatin AL | Pravastatin almus | Pravastatin Aurus | Pravastatin Corax | Pravastatin CT | Pravastatin dura | Pravastatin Heumann | Pravastatin hexal | Pravastatin Isis | Pravastatin ratiopharm | Pravastatin sandoz | Pravastatin Stada | Pravastatin TAD | Pravastatin-1 A Pharma | Selipran | Sigaprava</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Lipina | Prascolend | Pravacol | Pravastatina Genfar</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Pravacol | Pravator</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Lipostat | Pravahexal | Pravastatin Accord | Pravastatin Nycomed | Pravastatin Pliva</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cholestate | Lipizad | Lipostat</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bristacol | Lipemol | Liplat | Minuscol | Prareduct | Pravastatina acost | Pravastatina actavis | Pravastatina almus | Pravastatina alter | Pravastatina Angenerico | Pravastatina Apotex | Pravastatina aurobindo | Pravastatina aurovistas | Pravastatina bayvit | Pravastatina bexal | Pravastatina cinfa | Pravastatina combix | Pravastatina Cuve | Pravastatina Davur | Pravastatina dermogeneris | Pravastatina Edigen | Pravastatina kern | Pravastatina Korhispana | Pravastatina merck | Pravastatina mylan pharmaceuticals | Pravastatina Normon | Pravastatina Pharmagenus | Pravastatina Qualigen | Pravastatina ratiopharm | Pravastatina Sandoz | Pravastatina Tarbis | Pravastatina Tecnigen | Pravastatina ur | Pravastatina Vir | Pravastatina Winthrop | Pritadol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Pravachol | Pravastatin Alternova | Pravastatin arrow | Pravastatin hexal | Pravastatin Orion | Pravastatin ranbaxy | Pravastatin ratiopharma | Pravastatin sandoz | Pravastatin Winthrop</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Elisor | Pravastatine | Pravastatine Accord | Pravastatine actavis | Pravastatine Almus | Pravastatine Alter | Pravastatine Arrow | Pravastatine Biogaran | Pravastatine Bouchara Recordati | Pravastatine cristers | Pravastatine eg | Pravastatine Evolugen | Pravastatine evolugen pharma | Pravastatine gerda | Pravastatine Isomed | Pravastatine Lbr | Pravastatine merck | Pravastatine phr lab | Pravastatine Qualimed | Pravastatine ratiopharm | Pravastatine RPG | Pravastatine Sandoz | Pravastatine teva | Pravastatine Zydus | Vasten</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lipostat | Pravastatin | Pravastatin almus | Pravastatin arrow | Pravastatin cox | Pravastatin focus | Pravastatin kent | Pravastatin medreich | Pravastatin ntn | Pravastatin sandoz</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Asto-chol | Lipoprav | Maxudin | Ositron | Pravachol | Pravadium | Pravafact | Pravalip | Pravalong | Pravanox | Pravostin | Privast | Sosmin | Vastil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo pravastatin | Pms Pravastatin | Pravachol</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Statim</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Nikron | Prastin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cholespar | Invastin | Koleskol | Mevachol | Mevalotin | Novales | Pravachol | Pravastatin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bellprav | Beneprav | Bystat | Lipaprav | Lipostat | Lipovas | Pravamel | Pravastatin | Pravastatin teva | Pravat | Pravitin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Lipidal | Pravalip | Pravastatin teva</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Prastatin | Pravator | Prestatin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Adrestat | Aplactin | Prasterol | Pravaselect | Pravastatina | Pravastatina Acco | Pravastatina actavis | Pravastatina almus | Pravastatina Arrow | Pravastatina aurobindo | Pravastatina Doc | Pravastatina EG | Pravastatina Fg | Pravastatina Fidia | Pravastatina Ipso pharma | Pravastatina MG | Pravastatina mylan | Pravastatina Ranbaxy | Rastanit | Sanaprav | Selectin | Setac | Vasticor</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Lipostat | Lowchol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alsetin | Cholerit | Maibastan | Mevalation | Mevalect | Mevalilin | Mevalocut | Mevalotin | Mevan | Mevarich | Mevarich kaken | Mevasrolin | Mevastan | Mevatorte | Mindorotin | Pramevan | Pravalon | Pravamate | Pravapeak | Pravastan | Pravastan chemiphar | Pravastatin Na | Pravastatin na kn | Pravastatin na me | Pravastatin Sododium Tsuruhara | Pravatin | Provatin | Tatsuplamin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mevalotin | Mevarotin | Mevatin | Pavatin | Prastan | Pratan | Pravastar | Pravastatin | Stapra | Vasopran</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Lipostat</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo pravastatin | Lipostat | Pravastatine | Stavacor</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Lipostat | Pravahexal | Pravastatin Pliva | Pravastatin ratiopharm</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Docpravastatine | Prareduct | Pravasine | Pravasor | Pravastatin hexal</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lipostat | Pravastatin | Pravastatin-1 A Pharma | Pravastatina Pliva</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Elisor | Pravastatine Gt | Pravator</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Accogard | Apotivaz | Astin-10 | Astin-20 | Brakhor | Brufincol | Celuterol | Colpradin | Daxon t | Emipastin | Fepina | Genoestatina | Glicosar | Kenstatin | Kenvastin | Lemma ld | Lexet | Loretsin | Mavitina | Novina | Paver | Piflaxan | Prascolend | Prasiver | Pravacol | Pravastatin | Pravastatin landsteiner | Pravastatina | Pravastatina bayer | Pravastatina brissa | Pravastatina GI | Pravastatina gi ke | Pravastatina nafar | Striacol | Tratinal | Trydanil H | Valprastin | Vapradem | Varlex | Venxicor | Xipral</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo pravastatin | Avaco | Pratin | Pravachol | Pravatas | Pravid</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Elisor | Lipostat | Pravachol | Pravastatin Na | Pravastatine | Pravastatine A | Pravastatine na | Pravastatine Na CF | Pravastatine Na Merck | Pravastatine ranbaxy | Pravastatinenatrium Accord | Pravastatinenatrium alpharma | Pravastatinenatrium Gf | Pravastatinenatrium Katwijk | Pravastatinenatrium PCH | Pravastatinenatrium ratiopharm | Pravastatinenatrium Sandoz | Sanaprav | Selektine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Pravachol | Pravastatin | Pravastatin Nycomed | Pravastatin sandoz | Pravastatin teva</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo pravastatin | Cholvastin | Lipostat | Pravastatin mylan</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Pravacol | Pravastatina | Pravastine | Pravator</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Lipostat | Pravaz</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Lipostat | Nupra | Pralip | Pranu | Pravachol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo prava | Lipostat | Pravator</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Pravachol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Pravacol | Pravastatina | Pravastatina alter | Pravastatina aurobindo | Pravastatina bluepharma | Pravastatina bluesar | Pravastatina Ciclum | Pravastatina cinfa | Pravastatina generis | Pravastatina germed | Pravastatina lizatrovarin | Pravastatina mepha | Pravastatina mylan | Pravastatina Sandoz | Pravastatina Sivatca | Pravastatina Stada | Pritanol | Sanaprav</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lipostat</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Lipostat</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Lipostat | Pravastatin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lipostat</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Pravachol | Pravastatin arrow | Pravastatin copyfarm | Pravastatin ranbaxy | Pravastatin sandoz | Pravastatin teva</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Pravachol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Pravastatin teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Lipostat</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Mevalotin | Pravatas</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Elisor | Pravast | Pravastatin | Pravastatine winthrop | Pravastatine zentiva</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Pravachol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dehypotin Protect | Joinlo | Maxatin | Mevalotin | Mevalotin protect | Pavadin | Pavatin Protect | Perastin | Pratin | Pravastatin Na | U-prava</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Pravastatin sandoz</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mevalotin | Pravacol | Pravastatina</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agivastar | Fasthan | Hypevas | Hypravas</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Arrow pravastatin | Aspen Pravastatin | Colite | Novales | Pixeta | Pranalip | Prava | Pravacor</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31715077">
<a name="31715077"></a>Ahmed A, Williams DJ, Cheed V, et al; StAmP trial Collaborative Group. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo- controlled trial. <i>BJOG</i>. 2020;127(4):478-488. doi:10.1111/1471-0528.16013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/31715077/pubmed" id="31715077" target="_blank">31715077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30443347">
<a name="30443347"></a>Akimoto H, Negishi A, Oshima S, et al. Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs. <i>Pharmacol Res Perspect</i>. 2018;6(6):e00439. doi:10.1002/prp2.439<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/30443347/pubmed" id="30443347" target="_blank">30443347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25784688">
<a name="25784688"></a>Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. <i>BMJ</i>. 2015;350:h1035. doi:10.1136/bmj.h1035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/25784688/pubmed" id="25784688" target="_blank">25784688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16581330">
<a name="16581330"></a>Bays H. Statin safety: an overview and assessment of the data--2005. <i>Am J Cardiol</i>. 2006;97(8A):6C-26C. doi:10.1016/j.amjcard.2005.12.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/16581330/pubmed" id="16581330" target="_blank">16581330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15198967">
<a name="15198967"></a>Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. <i>Circulation</i>. 2004;109(23)(suppl 1):III50-III57. doi:10.1161/01.CIR.0000131519.15067.1f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/15198967/pubmed" id="15198967" target="_blank">15198967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21889469">
<a name="21889469"></a>Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. <i>J Hepatol</i>. 2012;56(2):374-380. doi:10.1016/j.jhep.2011.07.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/21889469/pubmed" id="21889469" target="_blank">21889469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27860156">
<a name="27860156"></a>Björnsson ES. Hepatotoxicity of statins and other lipid-lowering agents. <i>Liver Int</i>. 2017;37(2):173-178. doi:10.1111/liv.13308<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/27860156/pubmed" id="27860156" target="_blank">27860156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32139553">
<a name="32139553"></a>Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. <i>Gut</i>. 2020;69(5):953-962. doi:10.1136/gutjnl-2019-318237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/32139553/pubmed" id="32139553" target="_blank">32139553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30527143">
<a name="30527143"></a>Brunham LR, Ruel I, Aljenedil S, et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia: update 2018. <i>Can J Cardiol</i>. 2018;34(12):1553-1563. doi:10.1016/j.cjca.2018.09.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/30527143/pubmed" id="30527143" target="_blank">30527143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20360293">
<a name="20360293"></a>Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. <i>Mayo Clin Proc</i>. 2010;85(4):349-356. doi:10.4065/mcp.2009.0365<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/20360293/pubmed" id="20360293" target="_blank">20360293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15131789">
<a name="15131789"></a>Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. <i>Gastroenterology</i>. 2004;126(5):1287-1292. doi:10.1053/j.gastro.2004.02.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/15131789/pubmed" id="15131789" target="_blank">15131789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34967881">
<a name="34967881"></a>Chang JC, Chen YJ, Chen IC, Lin WS, Chen YM, Lin CH. Perinatal outcomes after statin exposure during pregnancy. <i>JAMA Netw Open</i>. 2021;4(12):e2141321. doi:10.1001/jamanetworkopen.2021.41321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/34967881/pubmed" id="34967881" target="_blank">34967881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24829162">
<a name="24829162"></a>Chen GL, Hsiao FY, Dong YH, Shen LJ, Wu FL. Statins and the risk of liver injury: a population-based case-control study. <i>Pharmacoepidemiol Drug Saf</i>. 2014;23(7):719-725. doi:10.1002/pds.3646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/24829162/pubmed" id="24829162" target="_blank">24829162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26723196">
<a name="26723196"></a>Costantine MM, Cleary K, Hebert MF, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high- risk pregnant women: a pilot randomized controlled trial. <i>Am J Obstet Gynecol</i>. 2016;214(6):720.e1-720.e17. doi:10.1016/j.ajog.2015.12.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/26723196/pubmed" id="26723196" target="_blank">26723196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34033812">
<a name="34033812"></a>Costantine MM, West H, Wisner KL, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Centers (OPRC) Network, Bethesda, MD. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. <i>Am J Obstet Gynecol</i>. 2021;225(6):666.e1-666.e15. doi:10.1016/j.ajog.2021.05.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/34033812/pubmed" id="34033812" target="_blank">34033812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20643330">
<a name="20643330"></a>Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2010;29(8):914-956. doi:10.1016/j.healun.2010.05.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/20643330/pubmed" id="20643330" target="_blank">20643330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18596007">
<a name="18596007"></a>Daniels SR, Greer FR; Committee on Nutrition. Lipid Screening and Cardiovascular Health in Childhood. <i>Pediatrics</i>. 2008;122(1):198-208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/18596007/pubmed" id="18596007" target="_blank">18596007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12398573">
<a name="12398573"></a>de Denus S, Spinler SA. Early Statin Therapy for Acute Coronary Syndromes. <i>Ann Pharmacother</i>. 2002;36(11):1749-1758.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/12398573/pubmed" id="12398573" target="_blank">12398573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15327593">
<a name="15327593"></a>de Graaf L, Brouwers AH, Diemont WL. Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?. <i>Br J Clin Pharmacol</i>. 2004;58(3):326-328. doi:10.1111/j.1365-2125.2004.02128.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/15327593/pubmed" id="15327593" target="_blank">15327593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eisen.1">
<a name="Eisen.1"></a>Eisen HJ, Rosenson RS, Johnson S. Heart transplantation: hyperlipidemia after transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 26, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30430215">
<a name="30430215"></a>Essers D, Schäublin M, Kullak-Ublick GA, Weiler S. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase. <i>Eur J Clin Pharmacol</i>. 2019;75(3):409-416. doi:10.1007/s00228-018-2589-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/30430215/pubmed" id="30430215" target="_blank">30430215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085961">
<a name="25085961"></a>Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):e278-e333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/25085961/pubmed" id="25085961" target="_blank">25085961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9403282">
<a name="9403282"></a>Gehr TW, Sica DA, Slugg PH, Hammett JL, Raymond R, Ford NF. The pharmacokinetics of pravastatin in patients on chronic hemodialysis. <i>Eur J Clin Pharmacol</i>. 1997;53(2):117-121. doi:10.1007/s002280050348<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/9403282/pubmed" id="9403282" target="_blank">9403282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586774">
<a name="30586774"></a>Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i>. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/30586774/pubmed" id="30586774" target="_blank">30586774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31842780">
<a name="31842780"></a>Guo M, Zhao J, Zhai Y, Zang P, Lv Q, Shang D. A prospective study of hepatic safety of statins used in very elderly patients. <i>BMC Geriatr</i>. 2019;19(1):352. doi:10.1186/s12877-019-1361-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/31842780/pubmed" id="31842780" target="_blank">31842780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16027406">
<a name="16027406"></a>Gustavson LE, Schweitzer SM, Koehne-Voss S, et al. The Effects of Multiple Doses of Fenofibrate on the Pharmacokinetics of Pravastatin and Its 3-Alpha-Hydroxy Isomeric Metabolite. <i>J Clin Pharmacol</i>. 2005;45(8):947-953.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/16027406/pubmed" id="16027406" target="_blank">16027406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1613121">
<a name="1613121"></a>Halstenson CE, Triscari J, DeVault A, Shapiro B, Keane W, Pan H. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. <i>J Clin Pharmacol</i>. 1992;32(2):124-132. doi:10.1002/j.1552-4604.1992.tb03816.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/1613121/pubmed" id="1613121" target="_blank">1613121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28531241">
<a name="28531241"></a>Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: The ALLHAT-LLT randomized clinical trial. <i>JAMA Intern Med</i>. 2017;177(7):955-965.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/28531241/pubmed" id="28531241" target="_blank">28531241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20628837">
<a name="20628837"></a>Harper CR, Jacobson TA. Evidence-based management of statin myopathy. <i>Curr Atheroscler Rep</i>. 2010;12(5):322-330. doi:10.1007/s11883-010-0120-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/20628837/pubmed" id="20628837" target="_blank">20628837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10235223">
<a name="10235223"></a>Hartleb M, Rymarczyk G, Januszewski K. Acute cholestatic hepatitis associated with pravastatin. <i>Am J Gastroenterol</i>. 1999;94(5):1388-1390. doi:10.1111/j.1572-0241.1999.01091.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/10235223/pubmed" id="10235223" target="_blank">10235223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12891228">
<a name="12891228"></a>Hedman M, Neuvonen PJ, Neuvonen M, et al. Pharmacokinetics and Pharmacodynamics of Pravastatin in Children With Familial Hypercholesterolemia. <i>Clin Pharmacol Ther</i>. 2003;74(2):178-185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/12891228/pubmed" id="12891228" target="_blank">12891228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064599">
<a name="22064599"></a>Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2011;124(23):e652-735.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/22064599/pubmed" id="22064599" target="_blank">22064599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29496886">
<a name="29496886"></a>Hilton-Jones D. Statin-related myopathies. <i>Pract Neurol</i>. 2018;18(2):97-105. doi:10.1136/practneurol-2017-001738<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/29496886/pubmed" id="29496886" target="_blank">29496886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32729746">
<a name="32729746"></a>Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. <i>Expert Opin Drug Metab Toxicol</i>. 2020;16(9):809-822. doi:10.1080/17425255.2020.1801634<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/32729746/pubmed" id="32729746" target="_blank">32729746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22936996">
<a name="22936996"></a>Hoffman KB, Kraus C, Dimbil M, Golomb BA. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. <i>PLoS One</i>. 2012;7(8):e42866. doi:10.1371/journal.pone.0042866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/22936996/pubmed" id="22936996" target="_blank">22936996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28551957">
<a name="28551957"></a>Holmsen ST, Bakkebø T, Seferowicz M, Retterstøl K. Statins and breastfeeding in familial hypercholesterolaemia. <i>Tidsskr Nor Laegeforen</i>. 2017;137(10):686-687. doi:10.4045/tidsskr.16.0838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/28551957/pubmed" id="28551957" target="_blank">28551957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26184102">
<a name="26184102"></a>Huang CY, Chung SD, Kao LT, Lin HC, Wang LH. Statin use is associated with bladder pain syndrome/interstitial cystitis: a population-based case-control study. <i>Urol Int</i>. 2015;95(2):227-232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/26184102/pubmed" id="26184102" target="_blank">26184102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28437620">
<a name="28437620"></a>Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi:10.4158/EP171764.APPGL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/28437620/pubmed" id="28437620" target="_blank">28437620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26957864">
<a name="26957864"></a>Jose J. Statins and its hepatic effects: Newer data, implications, and changing recommendations. <i>J Pharm Bioallied Sci</i>. 2016;8(1):23-28. doi:10.4103/0975-7406.171699<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/26957864/pubmed" id="26957864" target="_blank">26957864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17978161">
<a name="17978161"></a>Kalomenidis I, Papiris S, Loukides S. Bilateral pleural effusions associated with pravastatin sodium treatment. <i>Eur Respir J</i>. 2007;30(5):1022. doi:10.1183/09031936.00087007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/17978161/pubmed" id="17978161" target="_blank">17978161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32313740">
<a name="32313740"></a>Khan AA, Ahmed S, Mohammed A, Elzouki AY. Autoimmune-like drug-induced liver injury caused by atorvastatin and demonstration of the safety profile of pravastatin: A case report and literature review. <i>Cureus</i>. 2020;12(3):e7299. doi:10.7759/cureus.7299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/32313740/pubmed" id="32313740" target="_blank">32313740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18637891">
<a name="18637891"></a>Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. <i>Br J Clin Pharmacol</i>. 2008;66(4):572-574.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/18637891/pubmed" id="18637891" target="_blank">18637891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15860377">
<a name="15860377"></a>Launay-Vacher V, Izzedine H, Deray G. Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. <i>Int J Cardiol</i>. 2005;101(1):9-17. doi:10.1016/j.ijcard.2004.04.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/15860377/pubmed" id="15860377" target="_blank">15860377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22480340">
<a name="22480340"></a>Lecarpentier E, Morel O, Fournier T, et al. Statins and Pregnancy: Between Supposed Risks and Theoretical Benefits. <i>Drugs</i>. 2012;72(6):773-788.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/22480340/pubmed" id="22480340" target="_blank">22480340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lentine.1">
<a name="Lentine.1"></a>Lentine KL, Brennan DC. Kidney transplantation in adults: lipid abnormalities after kidney transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17668878">
<a name="17668878"></a>Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R; Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. <i>Hepatology</i>. 2007;46(5):1453-1463. doi:10.1002/hep.21848<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/17668878/pubmed" id="17668878" target="_blank">17668878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36031461">
<a name="36031461"></a>Lloyd-Jones DM, Morris PB, Ballantyne CM, et al; Writing Committee. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/36031461/pubmed" id="36031461" target="_blank">36031461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26886523">
<a name="26886523"></a>Mammen AL. Statin-associated autoimmune myopathy. <i>N Engl J Med</i>. 2016;374(7):664-669. doi:10.1056/NEJMra1515161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/26886523/pubmed" id="26886523" target="_blank">26886523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29301631">
<a name="29301631"></a>Mortensen MB, Falk E. Primary prevention with statins in the elderly. <i>J Am Coll Cardiol</i>. 2018;71(1):85-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/29301631/pubmed" id="29301631" target="_blank">29301631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24070396">
<a name="24070396"></a>Nanovskaya TN, Patrikeeva SL, Paul J, et al. Transplacental transfer and distribution of pravastatin. <i>Am J Obstet Gynecol</i>. 2013;209(4):373.e1-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/24070396/pubmed" id="24070396" target="_blank">24070396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.1">
<a name="NHLBI.1"></a>National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines. National Institutes of Health; 2011. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf%20" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf </a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28277343">
<a name="28277343"></a>Nazir S, Lohani S, Tachamo N, Poudel D, Donato A. Statin-associated autoimmune myopathy: a systematic review of 100 cases. <i>J Clin Rheumatol</i>. 2017;23(3):149-154. doi:10.1097/RHU.0000000000000497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/28277343/pubmed" id="28277343" target="_blank">28277343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30580575">
<a name="30580575"></a>Newman CB, Preiss D, Tobert JA, et al; American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin safety and associated adverse events: A scientific statement from the American Heart Association. <i>Arterioscler Thromb Vasc Biol</i>. 2019;39(2):e38-e81. doi:10.1161/ATV.0000000000000073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/30580575/pubmed" id="30580575" target="_blank">30580575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22091490">
<a name="22091490"></a>Newson RS, Felix JF, Heeringa J, Hofman A, Witteman JC, Tiemeier H. Association between serum cholesterol and noncardiovascular mortality in older age. <i>J Am Geriatr Soc</i>. 2011;59(10):1779-1785.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/22091490/pubmed" id="22091490" target="_blank">22091490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7606882">
<a name="7606882"></a>Nishizawa Y, Shoji T, Emoto M, et al. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. <i>Clin Nephrol</i>. 1995;43(4):268-277.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/7606882/pubmed" id="7606882" target="_blank">7606882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16006732">
<a name="16006732"></a>Ohmura C, Watada H, Hirose T, Tanaka Y, Kawamori R. Acute onset and worsening of diabetes concurrent with administration of statins. <i>Endocr J</i>. 2005;52(3):369-372. doi:10.1507/endocrj.52.369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/16006732/pubmed" id="16006732" target="_blank">16006732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3220964">
<a name="3220964"></a>Pan H, Fleiss P, Moore L, et al. Excretion of Pravastatin, an HMG CoA Reductase Inhibitor, in Breast Milk of Lactating Women. American College of Clinical Pharmacology seventeenth annual meeting. October 31-November 3, 1988, Orlando, Florida. Abstracts. <i>J Clin Pharmacol</i>. 1988;28(10):942.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/3220964/pubmed" id="3220964" target="_blank">3220964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33779213">
<a name="33779213"></a>Parikh NI, Gonzalez JM, Anderson CAM, et al; American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Stroke Council. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association. <i>Circulation</i>. 2021;143(18):e902-e916. doi:10.1161/CIR.0000000000000961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/33779213/pubmed" id="33779213" target="_blank">33779213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33781847">
<a name="33781847"></a>Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. <i>Can J Cardiol</i>. 2021:S0828-282X(21)00165-3. doi:10.1016/j.cjca.2021.03.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/33781847/pubmed" id="33781847" target="_blank">33781847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2116260">
<a name="2116260"></a>Pan HY, DeVault AR, Swites BJ, et al, "Pharmacokinetics and Pharmacodynamics of Pravastatin Alone and With Cholestyramine in Hypercholesterolemia," <i>Clin Pharmacol Ther</i>, 1990, 48(2):201-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/2116260/pubmed" id="2116260" target="_blank">2116260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25075655">
<a name="25075655"></a>Perdices EV, Medina-Cáliz I, Hernando S, et al. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. <i>Rev Esp Enferm Dig</i>. 2014;106(4):246-254.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/25075655/pubmed" id="25075655" target="_blank">25075655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pignone.2020">
<a name="Pignone.2020"></a>Pignone M. Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pravachol.1">
<a name="Pravachol.1"></a>Pravachol (pravastatin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pravachol.2">
<a name="Pravachol.2"></a>Pravachol (pravastatin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; June 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16609346">
<a name="16609346"></a>Purvin V, Kawasaki A, Smith KH, Kesler A. Statin-associated myasthenia gravis: report of 4 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2006;85(2):82-85. doi:10.1097/01.md.0000209337.59874.aa<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/16609346/pubmed" id="16609346" target="_blank">16609346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16226165">
<a name="16226165"></a>Ray KK and Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. <i>J Am Coll Cardiol</i>. 2005;46(8):1425-1433.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/16226165/pubmed" id="16226165" target="_blank">16226165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenson.3">
<a name="Rosenson.3"></a>Rosenson RS. Statins: Actions, side effects, and administration. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenson.1">
<a name="Rosenson.1"></a>Rosenson RS, Durrington P. Familial hypercholesterolemia in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 3, 2020a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenson.2">
<a name="Rosenson.2"></a>Rosenson RS, Hayward RA, Lopez-Sendon J. Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.<a href="http://www.uptodate.com" target="_blank"> http://www.uptodate.com</a>. Accessed June 3, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19826975">
<a name="19826975"></a>Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. <i>Semin Liver Dis</i>. 2009;29(4):412-422. doi:10.1055/s-0029-1240010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/19826975/pubmed" id="19826975" target="_blank">19826975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24700436">
<a name="24700436"></a>Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. <i>Hepatology</i>. 2014;60(2):679-686. doi:10.1002/hep.27157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/24700436/pubmed" id="24700436" target="_blank">24700436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34951046">
<a name="34951046"></a>Saito J, Kaneko K, Abe S, et al. Pravastatin concentrations in maternal serum, umbilical cord serum, breast milk and neonatal serum during pregnancy and lactation: a case study. <i>J Clin Pharm Ther</i>. Published online December 23, 2021. doi:10.1111/jcpt.13590<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/34951046/pubmed" id="34951046" target="_blank">34951046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29473763">
<a name="29473763"></a>Selva-O'Callaghan A, Alvarado-Cardenas M, Pinal-Fernández I, et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. <i>Expert Rev Clin Immunol</i>. 2018;14(3):215-224. doi:10.1080/1744666X.2018.1440206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/29473763/pubmed" id="29473763" target="_blank">29473763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18001622">
<a name="18001622"></a>Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. <i>Curr Atheroscler Rep</i>. 2007;9(5):389-396. doi:10.1007/s11883-007-0050-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/18001622/pubmed" id="18001622" target="_blank">18001622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12457784">
<a name="12457784"></a>Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. <i>Lancet</i>. 2002;360(9346):1623-1630.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/12457784/pubmed" id="12457784" target="_blank">12457784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Singh.1">
<a name="Singh.1"></a>Singh KN, Mejia P, Lady K, Singh A, Carey W. Safety of statins in decompensated cirrhosis in patients listed for liver transplantation [abstract 965].<i> Am J Gastroenterol.</i> 2019;114:S561-S562. doi:10.14309/01.ajg.0000593396.52814.ce</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27484241">
<a name="27484241"></a>Skilving I, Eriksson M, Rane A, Ovesjö ML. Statin-induced myopathy in a usual care setting-a prospective observational study of gender differences. <i>Eur J Clin Pharmacol</i>. 2016;72(10):1171-1176. doi:10.1007/s00228-016-2105-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/27484241/pubmed" id="27484241" target="_blank">27484241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14696880">
<a name="14696880"></a>Smith DJ, Olive KE. Chinese red rice-induced myopathy. <i>South Med J</i>. 2003;96(12):1265-1267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/14696880/pubmed" id="14696880" target="_blank">14696880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29684459">
<a name="29684459"></a>Speliotes EK, Balakrishnan M, Friedman LS, Corey KE. Treatment of dyslipidemia in common liver diseases. <i>Clin Gastroenterol Hepatol.</i> 2018;16(8):1189-1196. doi:10.1016/j.cgh.2018.04.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/29684459/pubmed" id="29684459" target="_blank">29684459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24222016">
<a name="24222016"></a>Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(25 Suppl 2):S1-45. doi:10.1161/01.cir.0000437738.63853.7a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/24222016/pubmed" id="24222016" target="_blank">24222016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25694464">
<a name="25694464"></a>Stroes ES, Thompson PD, Corsini A, et al; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>Eur Heart J</i>. 2015;36(17):1012-1022. doi:10.1093/eurheartj/ehv043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/25694464/pubmed" id="25694464" target="_blank">25694464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33726685">
<a name="33726685"></a>Sung S, Al-Karaghouli M, Kalainy S, Cabrera Garcia L, Abraldes JG. A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. <i>BMC Gastroenterol.</i> 2021;21(1):120. doi:10.1186/s12876-021-01704-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/33726685/pubmed" id="33726685" target="_blank">33726685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10498240">
<a name="10498240"></a>Takei A, Chiba S. Rhabdomyolysis associated with pravastatin treatment for major depression. <i>Psychiatry Clin Neurosci</i>. 1999;53(4):539. doi:10.1046/j.1440-1819.1999.00587.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/10498240/pubmed" id="10498240" target="_blank">10498240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34180257">
<a name="34180257"></a>Tarar ZI, Zafar MU, Ghous G, Farooq U, Shoukat HMH. Pravastatin-induced acute pancreatitis: a case report and literature review. <i>J Investig Med High Impact Case Rep</i>. 2021;9:23247096211028386. doi:10.1177/23247096211028386<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/34180257/pubmed" id="34180257" target="_blank">34180257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24729773">
<a name="24729773"></a>Thapar M, Russo MW, Bonkovsky HL. Statins and liver injury. <i>Gastroenterol Hepatol (N Y)</i>. 2013;9(9):605-606.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/24729773/pubmed" id="24729773" target="_blank">24729773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.2">
<a name="NHLBI.2"></a>“Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),” May 2001, www.nhlbi.nih.gov/guidelines/cholesterol.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16581332">
<a name="16581332"></a>Thompson PD, Clarkson PM, Rosenson RS; National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. <i>Am J Cardiol</i>. 2006;97(8A):69C-76C. doi:10.1016/j.amjcard.2005.12.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/16581332/pubmed" id="16581332" target="_blank">16581332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24323134">
<a name="24323134"></a>Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. <i>Ann Intern Med</i>. 2014;160(3):182. doi:10.7326/M13-2453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/24323134/pubmed" id="24323134" target="_blank">24323134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17109506">
<a name="17109506"></a>Tsigrelis C, Pitchumoni CS. Pravastatin: a potential cause for acute pancreatitis. <i>World J Gastroenterol</i>. 2006;12(43):7055-7057. doi:10.3748/wjg.v12.i43.7055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/17109506/pubmed" id="17109506" target="_blank">17109506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34044205">
<a name="34044205"></a>Vahedian-Azimi A, Makvandi S, Banach M, Reiner Ž, Sahebkar A. Fetal toxicity associated with statins: a systematic review and meta-analysis. <i>Atherosclerosis</i>. 2021a;327:59-67. doi:10.1016/j.atherosclerosis.2021a.05.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/34044205/pubmed" id="34044205" target="_blank">34044205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34601188">
<a name="34601188"></a>Vahedian-Azimi A, Bianconi V, Makvandi S, et al. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. <i>Atherosclerosis</i>. 2021b;336:1-11. doi:10.1016/j.atherosclerosis.2021.09.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/34601188/pubmed" id="34601188" target="_blank">34601188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28685504">
<a name="28685504"></a>Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. <i>Cochrane Database Syst Rev</i>. 2017;7:CD006401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/28685504/pubmed" id="28685504" target="_blank">28685504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30653440">
<a name="30653440"></a>Ward NC, Watts GF, Eckel RH. Statin toxicity. <i>Circ Res</i>. 2019;124(2):328-350. doi:10.1161/CIRCRESAHA.118.312782<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/30653440/pubmed" id="30653440" target="_blank">30653440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27754879">
<a name="27754879"></a>Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(21):e468-e495. doi:10.1161/CIR.0000000000000456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/27754879/pubmed" id="27754879" target="_blank">27754879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28839820">
<a name="28839820"></a>Wright AP, Adusumalli S, Corey KE. Statin therapy in patients with cirrhosis. <i>Frontline Gastroenterol.</i> 2015;6(4):255-261. doi:10.1136/flgastro-2014-100500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/28839820/pubmed" id="28839820" target="_blank">28839820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30716508">
<a name="30716508"></a>Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. <i>Am Heart J</i>. 2019;210:18-28. doi:10.1016/j.ahj.2018.12.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/30716508/pubmed" id="30716508" target="_blank">30716508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30032220">
<a name="30032220"></a>Zaleski AL, Taylor BA, Thompson PD. Coenzyme Q10 as treatment for statin-associated muscle symptoms-A good idea, but….<i> Adv Nutr</i>. 2018;9(4):519S-523S. doi:10.1093/advances/nmy010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pravastatin-pediatric-drug-information/abstract-text/30032220/pubmed" id="30032220" target="_blank">30032220</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12913 Version 517.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
